Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Colonic Neoplasms

ClinicalTrials.gov lists 2,389 trials for Colonic Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 114.

MeSH D003110 Neoplasms Neoplasm C04 C06
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 308 Phase 1/2 Phase 1/2 147 Phase 2 Phase 2 424 Phase 2/3 Phase 2/3 30 Phase 3 Phase 3 206 Phase 4 Phase 4 38 Not applicable Not applicable 675 Observational Observational 558 Phase 1 Phase 1 308 Phase 1/2 Phase 1/2 147 Phase 2 Phase 2 424 Phase 2/3 Phase 2/3 30 Phase 3 Phase 3 206 Phase 4 Phase 4 38 Not applicable Not applicable 675 Observational Observational 558

Trials per phase (log scale)

1 more section with rows

2,372 of the 2,389 trials are tagged with Colonic Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Colonic Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Colonic Neoplasms trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 136

1990: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 1991: 3 trials (Phase 3 2, Phase 2 1) 1993: 4 trials (Not applicable 1, Phase 3 3) 1994: 7 trials (Observational 1, Phase 3 4, Phase 2 1, Phase 1 1) 1995: 5 trials (Phase 3 1, Phase 2 2, Phase 1 2) 1996: 8 trials (Not applicable 1, Phase 3 2, Phase 2 4, Phase 1 1) 1997: 21 trials (Observational 1, Not applicable 2, Phase 3 6, Phase 2 3, Phase 1/2 5, Phase 1 4) 1998: 34 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2 10, Phase 1/2 2, Phase 1 10) 1999: 38 trials (Observational 2, Not applicable 1, Phase 3 7, Phase 2/3 1, Phase 2 16, Phase 1/2 3, Phase 1 8) 2000: 48 trials (Observational 3, Not applicable 4, Phase 3 11, Phase 2 12, Phase 1/2 8, Phase 1 10) 2001: 45 trials (Observational 2, Phase 3 8, Phase 2 18, Phase 1/2 5, Phase 1 12) 2002: 41 trials (Observational 8, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 18, Phase 1/2 3, Phase 1 6) 2003: 47 trials (Observational 8, Not applicable 3, Phase 3 8, Phase 2 16, Phase 1/2 1, Phase 1 11) 2004: 58 trials (Observational 6, Not applicable 5, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 21, Phase 1/2 6, Phase 1 10) 2005: 67 trials (Observational 7, Not applicable 11, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 16, Phase 1/2 3, Phase 1 15) 2006: 78 trials (Observational 20, Not applicable 11, Phase 4 1, Phase 3 9, Phase 2/3 1, Phase 2 24, Phase 1/2 3, Phase 1 9) 2007: 86 trials (Observational 23, Not applicable 16, Phase 4 2, Phase 3 7, Phase 2 19, Phase 1/2 5, Phase 1 14) 2008: 71 trials (Observational 20, Not applicable 10, Phase 4 1, Phase 3 15, Phase 2/3 2, Phase 2 6, Phase 1/2 7, Phase 1 10) 2009: 80 trials (Observational 17, Not applicable 18, Phase 3 3, Phase 2/3 3, Phase 2 20, Phase 1/2 3, Phase 1 16) 2010: 84 trials (Observational 16, Not applicable 17, Phase 4 2, Phase 3 8, Phase 2/3 3, Phase 2 21, Phase 1/2 6, Phase 1 11) 2011: 71 trials (Observational 18, Not applicable 20, Phase 4 1, Phase 3 3, Phase 2 12, Phase 1/2 3, Phase 1 14) 2012: 62 trials (Observational 16, Not applicable 19, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1/2 8, Phase 1 8) 2013: 74 trials (Observational 19, Not applicable 26, Phase 4 4, Phase 3 2, Phase 2 11, Phase 1/2 4, Phase 1 8) 2014: 64 trials (Observational 21, Not applicable 21, Phase 4 3, Phase 3 4, Phase 2/3 1, Phase 2 6, Phase 1 8) 2015: 65 trials (Observational 18, Not applicable 25, Phase 4 1, Phase 3 4, Phase 2/3 3, Phase 2 10, Phase 1/2 1, Phase 1 3) 2016: 70 trials (Observational 18, Not applicable 29, Phase 3 7, Phase 2/3 2, Phase 2 2, Phase 1/2 3, Phase 1 9) 2017: 104 trials (Observational 26, Not applicable 46, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 8, Phase 1/2 7, Phase 1 9) 2018: 103 trials (Observational 28, Not applicable 33, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 11, Phase 1/2 9, Phase 1 12) 2019: 112 trials (Observational 29, Not applicable 45, Phase 4 2, Phase 3 1, Phase 2/3 2, Phase 2 12, Phase 1/2 10, Phase 1 11) 2020: 117 trials (Observational 35, Not applicable 37, Phase 4 1, Phase 3 11, Phase 2 12, Phase 1/2 9, Phase 1 12) 2021: 133 trials (Observational 46, Not applicable 55, Phase 4 3, Phase 3 4, Phase 2/3 1, Phase 2 8, Phase 1/2 4, Phase 1 12) 2022: 136 trials (Observational 36, Not applicable 52, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 17, Phase 1/2 7, Phase 1 14) 2023: 122 trials (Observational 30, Not applicable 47, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 17, Phase 1/2 8, Phase 1 14) 2024: 114 trials (Observational 29, Not applicable 40, Phase 4 1, Phase 3 10, Phase 2/3 1, Phase 2 21, Phase 1/2 4, Phase 1 8) 2025: 106 trials (Observational 26, Not applicable 40, Phase 3 9, Phase 2 19, Phase 1/2 4, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 87
2025 106
2024 114
2023 122
2022 136
2021 133
2020 117
2019 112
2018 103
2017 104

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 206 trials still running at the 2026-10-09 snapshot; registered median of 33 months across 1,436 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Colonic Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 308
Phase 1/2 147
Phase 2 424
Phase 2/3 30
Phase 3 206
Phase 4 38
Not applicable 675
Observational 558
Expanded access 3

How many Colonic Neoplasms trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 85
Recruiting 264
Enrolling by invitation 16
Active, not recruiting 115
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Colonic Neoplasms trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 114
Amgen 15
European Organisation for Research and Treatment of Cancer - EORTC 15

Which drugs are being tested for Colonic Neoplasms? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Calcium Leucovorin 171
OXALIPLATIN 163
Irinotecan 133
"Capecitabine" 82
CETUXIMAB 79

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Fluorouracile 193
Bevacizumab 1 97
FOLFOX regimen 27
Adjuvant Therapy 25
FOLFIRI Regimen 20

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Colonic Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Diarrhea 456 54
Vomiting 442 79
Nausea 411 79
Pneumonia 407 42
Abdominal pain 403 72

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Colonic Neoplasms? (1,778)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design. Future oncology (London, England) 2026 Yes
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. The New England journal of medicine 2025 Yes
Prevalence of Endoscopically Curable Low-Risk Cancer Among Large (≥20 mm) Nonpedunculated Polyps in the Right Colon. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025 Yes
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers. Nature 2025 Yes
Clinical effect analysis of different regimens of capecitabine in the treatment of patients with advanced colon cancer. Journal of chemotherapy (Florence, Italy) 2025 Yes

Showing 5 of 1,778 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages